Glioblastoma Multiforme (GBM) Treatment Market Size, Share, Trends, & Industry Analysis Report
By Treatment (Surgery, Radiation therapy, Chemotherapy), By Drug Class, By End Use, and By Region – Market Forecast, 2025–2034
- Published Date:Sep-2025
- Pages: 110
- Format: PDF
- Report ID: PM2176
- Base Year: 2024
- Historical Data: 2020 - 2023
The global glioblastoma multiforme (GBM) treatment market was valued at USD 2.84 billion in 2024 and is expected to grow at a CAGR of 9.5 % during the forecast period. Key factors driving the market demand includes the increasing incidences of glioblastoma multiforme (GBM), favorable government policies, and support from non-government bodies and NGOs for raising funds.
Key Insights
- Radiation therapy accounted for the highest shares in 2024. This is due to advancements that further aid the development of more cost-effective and user-friendly products.
- The clinic segment is expected to witness rapid growth during the forecast period. This is due to the rising proliferation of non-invasive therapies.
- In 2024, North America accounted for the largest share due to the growing government funding initiatives and awareness programs regarding disease treatment.
- The Asia Pacific is expected to grow at a rapid pace attributed to the increase in the presence of a large patient pool associated with targeted diseases across the region.
Industry Dynamics
- Government and non-governmental bodies globally are educating people and raising awareness about the availability of glioblastoma multiforme (GBM), driving the growth opportunities.
- Increasing responsiveness towards the glioblastoma multiforme (GBM) and encouraging the population to contribute money for glioblastoma multiforme (GBM) research activities.
- Limiting the effectiveness of conventional and novel therapies creates a challenge, as the blood-brain barrier effectively blocks most drugs from reaching the tumor.
- Advancements in immunotherapy and targeted drug delivery are creating new opportunities.
Market Statistics
- 2024 Market Size: USD 2.84 billion
- 2034 Projected Market Size: USD 7.02 billion
- CAGR (2025-2034): 9.5%
- Largest market in 2024: North America
-treatment-market-size-by-region-2020-2034.png)
To Understand More About this Research: Request a Free Sample Report
The glioblastoma multiforme (GBM) treatment involves combination of surgery, radiation, and chemotherapy for removal, destruction, or slow recurrence of tumor cells. The growing number of brain tumors that are one of the deadliest forms of cancer may also accelerate the glioblastoma multiforme (GBM) market demand. A 2022 WHO report stated that the total number of brain CNS cases was 3,21,000.
The Stupp protocol faces challenges due to the nature of GMB tumors which often recurrs. The high need of medical has boosted the research and investment especially for novel therapies. This market is expected to witness growth in clinical trials for targeted therapies, immunotheraies, and advanced drug delivery systems to bypass the blood. Moreover, the rise in awareness for this disease are also supporting the market growth, as pharma companies and regulatory authorities accelerate the development and approval of efficient options for treatment.
Industry Dynamics
Growth Drivers
Several initiatives are carried out by various government and non-government bodies globally to educate people and raise awareness about the availability of glioblastoma multiforme (GBM). Additionally, these bodies are focusing on R&D activities and developing better surgical options for effective patient healing.
Consequently, this assists in increasing responsiveness towards the glioblastoma multiforme (GBM) and encouraging the population to contribute money for glioblastoma multiforme (GBM) research activities. Therefore, organizations such as the Brain Tumour Foundation of Canada, the National Brain Tumor Society, and the Cure Brain Cancer Foundation are contributing to various awareness programs and campaigns aimed at educating people about this condition.
In the United Kingdom, a campaign was established by members of the Brain Tumor Research charity in March, during Brain Tumor Awareness Month. The primary objective of the campaign is to increase awareness regarding the lack of financial support for brain tumor research and also assist people in better understanding brain tumors and their treatment options. Furthermore, Novocure conducts various activities to raise awareness about glioblastoma multiforme during Brain Tumor Awareness Month. Hence, these are the major driving factors for the global glioblastoma multiforme (GBM) treatment market demand.
-treatment-market-size-worth-usd-7.02-billion-by-2034.png)
Report Segmentation
The market is primarily segmented on the basis of treatment, drug class, end-use, and region.
|
By Treatment |
By Drug Class |
By End-use |
By Region |
|
|
|
|
Know more about this report: request for sample pages
Segmental Insights
Treatment Analysis
Radiation therapy accounted for the highest shares in 2024, owing to the technological breakthroughs in radiotherapy and improved survival rates. This advancement further aids more cost-effective and easy-to-use products with enhanced precision and effective drug delivery in treating diseases. Radiation therapy is predominantly offered as the initial treatment or combined with chemotherapy and surgery.
It is also productive and highly recommended for brain tumors in the event of recurrence. Thus, the growing acceptance of this surgery option in the treatment of brain tumors is contributing towards the segment growth across the globe. Further, the utilization of Temozolomide coupled with radiotherapy creates the tumor more sensitivity to radiation. This integration of therapy is more effective as compared to radiation without Temozolomide, which drives segmental growth worldwide.
Moreover, the surgery segment is projected to show the fastest CAGR in the near future. This surgery option is also penetrating for the eradication of cancer and brain tumors. Also, surgery is one of the most common treatments for GBM, followed by chemotherapy and radiation therapy. Furthermore, the growing usage of such therapy to manage the disease is anticipated to boost the segment growth over the foreseen period. Apart from this, the rise in research activities to develop new targeted therapy for the treatment of disease also drive the segment market demand over the approaching years.
End-use Analysis
The hospital segment is recorded with the largest shares in 2024 and is expected to lead the glioblastoma multiforme (GBM) market in the forecasting years. Hospitals are mainly preferred by patients for accessibility of treatment and convenience. Moreover, the rise in the number of surgeries performed and management to treat the GBM and the complexity related to the treatment are projected to drive the glioblastoma multiforme (GBM) market. In addition, the healthcare setting of hospitals is expanding at a rapid pace due to pooling investments in hospitals across developed and emerging economies.
The clinic segment is further projected to grow at a rapid rate during the forecast period. The rising proliferation of non-invasive therapies, including radiation therapy and tumor-treating fields therapy, is also expected to reinforce the segmental growth across the world. Increasing adoption of patient-oriented surgery options, such as tumor-treating fields therapy and external beam radiation therapy, is also creating a lucrative market demand for such products in clinical settlements. For instance, Johns Hopkins Medicine provides tumor-treating fields therapy, radiation therapy, and others for the treatment of brain disorders.
Regional Analysis
North America Glioblastoma Multiforme (GBM) Treatment Market Assessment
North America accounted for the largest share in the global glioblastoma multiforme (GBM) treatment market in 2024. Factors such as the growing government funding initiatives and awareness program regarding disease treatment, along with, the growing FDA approval for novel drugs in the market. For instance, in January 2025, Mayo Clinic announced the results of a treatment approach that is expected to improve overall survival in older patients with newly diagnosed glioblastoma while maintaining quality of life. The results showed that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. Furthermore, the easy availability of quality medical facilities, favorable reimbursement policies, and the rise in efforts into R&D of such drugs. Therefore, these factors may fuel the glioblastoma multiforme (GBM) market demand across North America in the forthcoming years.
Asia Pacific Glioblastoma Multiforme (GBM) Treatment Market Insights
Asia Pacific is expected to grow at the highest CAGR across the globe during the forecast year owing to the factors such as rising R&D activities in the healthcare sector along with the growing presence of a large patient pool associated with targeted diseases across the region. The healthcare infrastructure in the APAC has been further shifting toward novel and innovative methods in surgery options and making technological developments to heal severe diseases, including brain tumors. Hence, it may positively influence the market demand for glioblastoma multiforme (GBM) surgery to demand that creates lucrative opportunities for the glioblastoma multiforme (GBM) market across the Asia Pacific in the near future.
-treatment-market-trends-by-region-2020-2034.png)
Competitive Insight
Some of the major players operating the global glioblastoma multiforme (GBM) market include Amgen, Amneal Pharmaceuticals, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
Glioblastoma Multiforme (GBM) Treatment Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 2.84 billion |
| Market size value in 2025 | USD 3.10 billion |
|
Revenue forecast in 2034 |
USD 7.02 billion |
|
CAGR |
9.5 % from 2025 - 2034 |
|
Base year |
2024 |
|
Historical data |
2020 - 2023 |
|
Forecast period |
2025 - 2034 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2025 to 2034 |
|
Segments covered |
By Treatment, By Drug Class, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key Companies |
Amgen, Amneal Pharmaceuticals, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. |
FAQ's
• The global market size was valued at USD 2.84 billion in 2024 and is projected to grow to USD 7.02 billion by 2034.
• The global market is projected to register a CAGR of 9.5% during the forecast period.
• North America dominated the global market in 2024.
• A few key players are Amgen, Amneal Pharmaceuticals, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
• Radiation therapy accounted for the highest share in 2024.
• The clinic segment is expected to witness rapid growth during the forecast period.
© 2025 Polaris Market Research and Consulting. All rights reserved
